Glyconjugate Klebsiella pneumoniae bivalent vaccine

Phase 1Vaccine

Glyconjugate Klebsiella pneumoniae bivalent vaccine is one of 25 biologic programs targeting Pneumonia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

PneumoniaPhase 1

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Prevacid

Takeda

Preclinical

1 2

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 3

Zantac 150

CChattem

Preclinical

2 4

Alka-Seltzer

AAbbott

Preclinical

1 5

Pepcid

KKenvue Brands

Preclinical

1 6

Aciphex

Akero Therapeutics

Preclinical

1 7

Mucinex

AAultman Health Foundation

Preclinical

1 8

Tagamet

DDT MedTech, LLC

Preclinical

1 9

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 10

PCV13

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Pneumonia

NCT07016152

Clinical

Trials by Indication[1]

Pneumonia1 trial

An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults

Recruiting·CCho Pharma Inc.·Phase 1·NCT07016152·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Glyconjugate Klebsiella pneumoniae bivalent vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glyconjugate Klebsiella pneumoniae bivalent vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glyconjugate Klebsiella pneumoniae bivalent vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cho Pharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: CCho Pharma Inc.

Glyconjugate Klebsiella pneumoniae bivalent vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Pneumonia1 trial

References

Drug Info

Quick Facts

Related News